加强医疗创新 助力公共卫生发展

2017-11-19 佚名 新华网

新时代条件下医疗创新对支持公共卫生发展,特别是肺结核等易被忽视的传染性疾病防控的重大意义。

近日,结核病成为社会的关注热点。“其实,我国防控结核病的形势依然严峻。”11月17日,中国疾病预防控制中心结核病预防控制中心主任王黎霞在当日举行的“医疗创新与公共卫生发展研讨会”上表示,根据世界卫生组织(WHO)估计,中国的利福平耐药肺结核患者人数约占全世界的12%,肺结核尤其是利福平耐药肺结核依然威胁着我国居民的健康。

据悉,本次研讨会由国家卫生计生委疾病预防控制局指导、《健康报》社主办,旨在探讨新时代条件下医疗创新对支持公共卫生发展,特别是肺结核等易被忽视的传染性疾病防控的重大意义,助力健康中国建设、提升全民健康水平的深层社会价值。

健康需求攀升,疾病挑战严峻,医疗产业亟待创新升级

随着生活水平的提升及社会老龄化进程加速,我国人民对健康的需求和期盼也急剧攀升。近年来,我国当前公共卫生事业与疾病防控事业取得了很大的成绩,但在公共卫生领域,依然面临着人民群众日益增长的对美好生活的需要和不平衡不充分发展之间的矛盾。以结核病为例,数据显示,2016年,全球有1040万人患有结核病,170万人因该病死亡。中国每年肺结核病新发89.5万,耐药结核患者每年新发约7.3万例。结核病尤其是耐多药结核病(MDR-TB)依然是全球以及中国公共卫生领域最为严峻的挑战之一,亟待创新的医疗解决方案以应对疾病挑战。

《“健康中国2030”规划纲要》是未来十余年我国推进健康中国建设的行动纲领,提出了“以改革创新为动力、把创新融入公共卫生领域”。“科技创新是应对卫生与健康重大挑战的战略选择,是促进健康事业和健康产业良性发展的根本保证,是建设科技强国的重要组成部分。”中华预防医学会副会长孔灵芝指出,“同时,科技创新也是我们解决公共卫生领域存在的发展不平衡不充分矛盾的关键手段。”

“2010年,中国提前5年实现了联合国千年发展目标的结核病控制目标,过去的结核病防控成绩都与我国对医疗创新的重视,以及对结核病防控工作的战略发展规划紧密相关。但是,我国防控结核病的形势依然严峻。”王黎霞表示,耐多药结核病是一种由对异烟肼和利福平这两种一线抗结核药物都没有反应的细菌导致的结核病,是一项严重的公共卫生危机和卫生安全威胁。据世界卫生组织(WHO)估计,全球每年约有60万利福平耐药新发病例,其中有49万耐多药结核病患者,中国的利福平耐药肺结核患者人数约占全世界的12%。

协同构建创新生态,共筑健康中国防护网

当日,中国发展研究基金会副秘书长肖庆文介绍了《公共卫生领域的创新研究》项目,肖庆文说,“在抗击重大疾病、提升社会公共卫生水平和建设健康社会的过程中,创新是重要驱动力。我们希望从创新整个链条出发,研究创新如何在公共卫生领域提升疾病防控和健康管理能力,最终实现健康中国的总体目标。”

首都医科大学附属北京胸科医院副院长张宗德教授也强调了医疗创新在以耐多药结核病为例的公共卫生领域的重要性,“身为一线医务工作者,我们认为,除了药物管理模式、医患沟通模式等多方面的创新,关键性的药物创新也至关重要。”

今年10月,国家发布了《关于深化审评审评制度改革,鼓励药品医疗器械创新的意见》,内容着重促进创新、鼓励创新。“医疗创新对提升公共卫生水平、推进健康中国建设的积极意义。”《健康报》社副社长肖景丹表示,“作为媒体,聚焦创新前沿发展,传播健康社会理念,我们责无旁贷。希望能有更多人意识到医疗创新的重要价值,并积极加入到推进我国公共卫生建设的工作中来。”

当日还新发布了专题纪录片《抗击结核,我们共同的保卫战》,通过讲述社会各方携手创新对抗耐多药肺结核的真实故事,深刻反映医疗创新的社会价值。该纪录片导演周全、范士广在分享拍摄感受时表示,公共卫生不只与医生和患者有关,它关系到每个人、每个家庭在社会中的安全感,只有社会各方相互支持和关爱,不断提出创新的解决方案,才有底气面对疾病的挑战。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1741153, encodeId=180e1e4115367, content=<a href='/topic/show?id=108734851ea' target=_blank style='color:#2F92EE;'>#医疗创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34851, encryptionId=108734851ea, topicName=医疗创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02e734877294, createdName=ms24272190615788285182, createdTime=Mon Jun 18 21:51:00 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263275, encodeId=f5dd2632e5ae, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Wed Nov 22 07:24:16 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285469, encodeId=5e0a12854694e, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Tue Nov 21 01:51:00 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262604, encodeId=c533262604c4, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Nov 19 17:00:28 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262563, encodeId=3bee2625630f, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Nov 19 13:01:46 CST 2017, time=2017-11-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1741153, encodeId=180e1e4115367, content=<a href='/topic/show?id=108734851ea' target=_blank style='color:#2F92EE;'>#医疗创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34851, encryptionId=108734851ea, topicName=医疗创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02e734877294, createdName=ms24272190615788285182, createdTime=Mon Jun 18 21:51:00 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263275, encodeId=f5dd2632e5ae, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Wed Nov 22 07:24:16 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285469, encodeId=5e0a12854694e, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Tue Nov 21 01:51:00 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262604, encodeId=c533262604c4, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Nov 19 17:00:28 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262563, encodeId=3bee2625630f, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Nov 19 13:01:46 CST 2017, time=2017-11-19, status=1, ipAttribution=)]
    2017-11-22 sunfeifeiyang

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1741153, encodeId=180e1e4115367, content=<a href='/topic/show?id=108734851ea' target=_blank style='color:#2F92EE;'>#医疗创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34851, encryptionId=108734851ea, topicName=医疗创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02e734877294, createdName=ms24272190615788285182, createdTime=Mon Jun 18 21:51:00 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263275, encodeId=f5dd2632e5ae, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Wed Nov 22 07:24:16 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285469, encodeId=5e0a12854694e, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Tue Nov 21 01:51:00 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262604, encodeId=c533262604c4, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Nov 19 17:00:28 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262563, encodeId=3bee2625630f, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Nov 19 13:01:46 CST 2017, time=2017-11-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1741153, encodeId=180e1e4115367, content=<a href='/topic/show?id=108734851ea' target=_blank style='color:#2F92EE;'>#医疗创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34851, encryptionId=108734851ea, topicName=医疗创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02e734877294, createdName=ms24272190615788285182, createdTime=Mon Jun 18 21:51:00 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263275, encodeId=f5dd2632e5ae, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Wed Nov 22 07:24:16 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285469, encodeId=5e0a12854694e, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Tue Nov 21 01:51:00 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262604, encodeId=c533262604c4, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Nov 19 17:00:28 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262563, encodeId=3bee2625630f, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Nov 19 13:01:46 CST 2017, time=2017-11-19, status=1, ipAttribution=)]
    2017-11-19 1dd8c52fm63(暂无匿称)

    学习学习.继续关注

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1741153, encodeId=180e1e4115367, content=<a href='/topic/show?id=108734851ea' target=_blank style='color:#2F92EE;'>#医疗创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34851, encryptionId=108734851ea, topicName=医疗创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02e734877294, createdName=ms24272190615788285182, createdTime=Mon Jun 18 21:51:00 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263275, encodeId=f5dd2632e5ae, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Wed Nov 22 07:24:16 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285469, encodeId=5e0a12854694e, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Tue Nov 21 01:51:00 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262604, encodeId=c533262604c4, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Nov 19 17:00:28 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262563, encodeId=3bee2625630f, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Nov 19 13:01:46 CST 2017, time=2017-11-19, status=1, ipAttribution=)]
    2017-11-19 Y—xianghai

    学习了新知识

    0

相关资讯

世界头号传染病年致死170万人 几年才能有进展?

全球投入到艾滋病的研发资金约是投入到结核病的10倍,跨国药企研发治疗结核新药的意愿较弱。

世卫报告:全球终止结核病仍需加快步伐

世界卫生组织30日发布《2017年全球结核病报告》称,尽管多年来全世界终止结核病成就显著,但最新情况依然严峻,死亡和患病人数之多说明进展速度仍不够快,结核病仍是全球头号传染病杀手。

世界头号传染病年致死170万人 几年之内能否有进展?

全球投入到艾滋病的研发资金约是投入到结核病的10倍,跨国药企研发治疗结核新药的意愿较弱。

国家卫计委:全力救治湖南桃江结核病感染学生

11月17日,国家卫生计生委表示,对湖南省桃江第四中学结核病聚集性疫情高度重视,已责成当地核实情况,及时公开发布准确信息,全力以赴治疗患病学生。

安徽成立全国规模很大结核病专科医联体,包括77家医疗单位

结核病又被称为“白色瘟疫”,人人谈之色变。我(安徽)省是全国结核病负担较为严重省份,结核病一直以来被列为我省三大重点控制传染病之一。为贯彻落实《“十三五”安徽省结核病防治规划》,推进医疗卫生体制改革,2016年10月25日,在省卫计委领导下,作为我省结核病临床治疗中心,省胸科医院牵头成立了全国规模最大的结核病专科医联体。经过一年建设,我省结核病分级诊疗政策体系逐步完善,医疗卫生机构分工协作机制基本